Biosyngen, a leading pharmaceutical company, has announced that its groundbreaking product, BST02, has been granted Fast Track Designation (FTD) by the US Food and Drug Administration (FDA) for the treatment of all types of liver cancer, including hepatocellular carcinoma and cholangiocarcinoma.

Fast Track Designation is a special process designed to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening conditions, addressing unmet medical needs. This designation is expected to accelerate the progression of clinical trials and streamline the registration of pharmaceutical products for marketing purposes.

BST02, the first TIL cell therapy drug for liver cancer to advance to the clinical stage globally, received FDA approval for Phase I/II clinical trials in October 2023. Additionally, it obtained approval from the Center for Drug Evaluation (CDE) of the China National Drug Administration in January 2024. This achievement underscores Biosyngen's commitment to pioneering cell therapy for cancer treatment.

Another Biosyngen product, BRG01, had previously been granted Fast Track Designation in July 2023, further highlighting the company's dedication to addressing critical medical needs.

Michelle Chen, co-founder and CEO of Biosyngen, expressed gratitude to the FDA for acknowledging BST02 as the company's fourth product. She reiterated Biosyngen's commitment to advancing global cancer cell therapy and providing innovative treatment solutions for diverse patient populations. Chen emphasized the company's dedication to utilizing advanced technology platforms to offer more effective and accessible treatment options globally.

BST02, a T-cell therapy based on the expansion of the patient's tumor-infiltrating lymphocytes, falls under the category of adoptive immune cell therapy technology. Offering promise for the treatment of all types of liver cancer, BST02 stands out with its cryopreserved form, overcoming distance constraints, and a reduced need for high doses of interleukin-2 compared to traditional TIL therapies.

Biosyngen remains dedicated to the research and development of innovative pharmaceutical products to address unmet clinical needs in oncology. The company looks forward to maintaining its focus on advancing research in this domain for the betterment of patients worldwide.